Management of recurrent melanoma of the extremity

Two forms of therapy employed for treatment of patients with recurrent melanoma limited to the extremity, and carried out during different intervals of time, are presented. Perfusion of the involved extremity with phenylalanine mustard has resulted in a 5‐year survival rate of 28% in 43 patients. A...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 1975-03, Vol.35 (3), p.574-579
Main Authors: Shingleton, William W., Seigler, Hilliard F., Stocks, Lewis H., Downs, Robert W.
Format: Article
Language:English
Subjects:
Adult
Aged
Antigens, Neoplasm
BCG Vaccine - administration & dosage
BCG Vaccine - therapeutic use
Extremities
Female
Humans
Immunotherapy - methods
Lymphocyte Transfusion
Lymphocytes - immunology
Male
Melanoma - drug therapy
Melanoma - immunology
Melanoma - therapy
Melphalan - therapeutic use
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - therapy
Neuraminidase - pharmacology
Nitrogen Mustard Compounds - administration & dosage
Perfusion
Skin Neoplasms - drug therapy
Skin Neoplasms - therapy
Transplantation, Autologous
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two forms of therapy employed for treatment of patients with recurrent melanoma limited to the extremity, and carried out during different intervals of time, are presented. Perfusion of the involved extremity with phenylalanine mustard has resulted in a 5‐year survival rate of 28% in 43 patients. A second group of 25 patients has been treated by a four‐stage immunotherapy program consisting of sensitization with intradermal BCG, followed in 6 weeks by intra‐tumor injection of BCG. A third stage involved the activation of the patient's lymphocytes, after removal by a blood cell separator, incubated in vitro with irradiated neuraminidase‐treated melanoma cells and reintroduced into the patient either by subcutaneous or intratumor injection. The fourth stage of immunotherapy involves injection of an inoculum of irradiated neuraminidase‐treated autochothonous tumor cells plus BCG injected intratumorally or subcutaneously. Sixteen of 24 patients receiving immunotherapy treatment program have experienced arrest of their disease lasting from 5 to 42 months.
ISSN:0008-543X
1097-0142
DOI:10.1002/1097-0142(197503)35:3<574::AID-CNCR2820350303>3.0.CO;2-5